Exploring the Role of Overactive Bladder Acting Medications on Different Targets: A Pharmacological Intervention

Introduction: Overactive bladder (OAB) is a common disorder characterized by urine urgency, frequency, and incontinence, which has a substantial impact on quality of life. Current treatments, such as antimuscarinics and beta-3 agonists, frequently have limitations, including side effects and varying efficacy. Fesoterodine fumarate, a muscarinic receptor antagonist, has emerged as a treatment option; however, comprehensive analyses of its mechanisms, clinical efficacy, and potential alternatives are required. Methods: A thorough literature search was carried out using PubMed, Scopus, and Web of Science databases. The keywords used included "overactive bladder", "fesoterodine", "ion channels", and "pharmacological interventions". Studies were chosen based on their relevance, sample size, and methodological rigor. Data were combined to assess efficacy and safety and establish the patterns. Results: In clinical studies, fesoterodine has revealed considerable effectiveness in lowering OAB symptoms while maintaining a safety profile comparable to other anti-muscarinics. In preclinical investigations, novel medicines, such as TRP channel modulators (e.g., nifedipine) and enzymetargeting medications (e.g., PDE5 inhibitors), have shown promise. The drawbacks have been found to include diverse study designs and the underrepresentation of varied communities. Discussion: The present research study focused on pharmacological treatments for OAB, focusing on fesoterodine's mechanism of action, clinical trials, and novel medications targeting ion channels, enzymes, and the autonomic nervous system. Conclusion: The frequency and amount of urination are associated with the disease condition, stool movement, and emptying. Pathophysiological changes associated with the increased sensitivity in the gut, inflammatory response, and microbiota in the intestine largely affect the OAB.